Transposon Receives US FDA Fast Track Designation for TPN-101 for Progressive Supranuclear Palsy
2024-05-21
临床2期快速通道临床结果
Designation Supports Accelerated Drug Development for PSP
TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers of Neurodegeneration and Neuroinflammation in PSP
SAN DIEGO, May 21, 2024 /PRNewswire/ -- Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TPN-101 for progressive supranuclear palsy (PSP).
"Fast Track designation for TPN-101 is an important acknowledgement by the FDA of the critical need to find an effective treatment for PSP, a rare and devastating neurological disorder with no approved treatment options," said Dennis Podlesak, Chairman and Chief Executive Officer of Transposon. "We look forward to working collaboratively with the FDA to advance the development of TPN-101 as rapidly as possible for the treatment of PSP and other neurodegenerative diseases including ALS and Alzheimer's disease."
The designation of TPN-101 as a Fast Track product for PSP is supported by data from a Phase 2, randomized, double-blind, placebo-controlled study of TPN-101 in patients with PSP. In that study, TPN-101 was the first treatment for PSP to reduce levels of neurofilament light chain (NfL), a key biomarker of neurodegeneration in tauopathies such as PSP and Alzheimer's disease. TPN-101 also showed dose-related reductions in interleukin 6 (IL-6) cytokine levels, a biomarker of neuroinflammation that is elevated in PSP and correlates with disease progression and severity. Participants treated with TPN-101 for the entire 48-week trial duration showed a stabilization of their clinical symptoms as measured by the PSP Rating Scale (PSPRS) between weeks 24 and 48. Further information on the study can be accessed at ClinicalTrials.gov.
About Fast Track Designation
The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need. Fast Track status allows for enhanced communication and collaboration between the FDA and drug developers, potentially speeding up the delivery of life-saving treatments to patients.
About PSP
PSP is a rare neurodegenerative disorder that causes slowing of movement, loss of balance leading to falls, impaired eye movements, and disturbances in cognition and behavior. The disease typically affects people in their mid- to late-60s, and the mean survival for individuals with PSP is 6 to 7 years. There are currently no treatments capable of delaying the progression of the disease.
About Transposon
Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a platform of novel therapies for the treatment of neurodegenerative and aging-related diseases, including progressive supranuclear palsy, amyotrophic lateral sclerosis, frontotemporal dementia, and Alzheimer's disease. The company's lead clinical compound, TPN-101, is first-in-class to address LINE-1 reverse transcriptase for treating neurodegenerative and autoimmune diseases. The company also has a discovery platform supporting a deep pipeline of novel therapies to address additional indications.
About TPN-101
TPN-101 specifically inhibits the LINE-1 reverse transcriptase that promotes LINE-1 replication. LINE-1 elements are a class of retrotransposable elements that in humans are uniquely capable of replicating and moving to new locations within the genome. When this process becomes dysregulated, LINE-1 reverse transcriptase drives overproduction of LINE-1 DNA, triggering innate immune responses that contribute to neurodegenerative, autoimmune and aging-related disease pathology.
Contact:
Rick Orr
(858) 535-4821
[email protected]
SOURCE Transposon Therapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。